The manufacturers of
clopidogrel note that in various large
clinical studies in patients with acute coronary
syndrome or myocardial infarction, most patients received LMWHs without an obvious difference in the rate of bleeding or the
incidence of major bleeding. However, case reports describe occasional serious bleeding events in those given
clopidogrel with a LMWH.
Although concurrent use can be beneficial the manufacturers advise caution because of the possible risk of increased bleeding.